Harvest Health & Recreation Inc. Reports First Quarter 2021 Financial Results

  • First quarter revenue was $88.8 million , up 101% from the first quarter 2020 and 27% sequentially
  • First quarter net loss before non-controlling interest was $23.0 million , compared to $7.4 million in the fourth quarter 2020
  • Adjusted EBITDA was $26.9 million in the first quarter, up 196% compared to $9.1 million in the fourth quarter 2020
  • 2021 revenue target increased to at least $400 million

Harvest Health & Recreation Inc. ("Harvest" or the "Company") (CSE: HARV, OTCQX: HRVSF), a vertically integrated cannabis company and multi-state operator in the U.S., today reported its financial and operating results for the first quarter 2021. All financial information is provided in U.S. dollars unless otherwise indicated.

Harvest Health & Recreation, Inc. Logo (PRNewsfoto/Harvest Health & Recreation...)

First Quarter 2021 Financial Results

  • Total revenue in the first quarter was $88.8 million , an increase of 101% from $44.2 million in the first quarter of 2020, and up 27% compared to $69.9 million in the fourth quarter of 2020.
  • Gross profit in the first quarter was $47.9 million , compared to $18.1 million in the first quarter of 2020, and $31.3 million in the fourth quarter of 2020.
  • Gross profit margin in the first quarter was 53.9%, compared to 41.0% in the first quarter of 2020 and 44.8% in the fourth quarter of 2020.
  • Net loss before non-controlling interest was $23.0 million for the first quarter, compared to $7.4 million in the fourth quarter of 2020.
  • Adjusted EBITDA in the first quarter was $26.9 million , compared to $9.1 million in the fourth quarter of 2020.

Please see the supplemental information regarding the use of Non-GAAP Financial Measures, and a reconciliation of Non-GAAP Financial Measures.

First Quarter 2021 Business Highlights

  • On January 22, 2021 , Harvest recorded the first recreational cannabis sale in the state of Arizona at its Scottsdale location. Harvest began serving adult use customers in addition to medical patients at all 15 of its dispensaries on January 22 .
  • On January 25, 2021 , Harvest announced the closing of a sale leaseback transaction with Innovative Industrial Properties, Inc. Harvest sold a 292,000 square foot facility for $23.8 million . Harvest will operate the cultivation and processing facility and expects to receive up to $10.8 million in tenant improvements.
  • On February 22, 2021 , Harvest announced the divestiture of two medical marijuana dispensaries in Bismarck and Williston, North Dakota for an immaterial amount of cash.
  • On March 11, 2021 , Harvest opened one new dispensary in Whitehall, Pennsylvania .
  • On March 15, 2021 , Harvest announced the settlement of its dispute with Falcon International, Inc. In accordance with the settlement terms, Harvest now owns a 10% equity stake in Falcon and received a ten year warrant to purchase up to 20% of the company's shares at an exercise price of $1.91 per share.
  • As of March 31, 2021 , Harvest owned, operated, or managed 37 retail locations in six states, including 15 open dispensaries in Arizona .

Recent Developments

  • Harvest opened two new medical retail dispensaries in Florida on May 5 th and May 6 th in Olympia Heights and West Palm Beach .
  • On May 7, 2021 , Harvest announced that a settlement was reached regarding the grower/processor permittee AGRiMED Industries of PA, LLC.
  • On May 10, 2021 , Trulieve announced its planned acquisition of Harvest. Each Harvest shareholder is expected to receive 0.117 shares of Trulieve for each Harvest share, representing total consideration of approximately $2.1 billion . The implied price per Harvest share is equal to $4.79 , representing a 34% premium to the May 7, 2021 closing price of the Harvest shares.

Outlook
Harvest is raising its full year 2021 revenue target to at least $400 million . Reported gross margins are expected to be at or above 50% and will likely continue to fluctuate from quarter to quarter.

Management Commentary
"Our first quarter results show the benefits of reaching impactful milestones such as the launch of recreational sales in Arizona " said Chief Executive Officer Steve White . "We are focused on our key operational and financial priorities in 2021 as we continue to build on this positive momentum."

Conference Call & Webcast
Harvest Health and Recreation Inc. will host a conference call and audio webcast with Chief Executive Officer Steve White , Monday May 10, 2021 at 8:00 AM Eastern Time .

Registration for this event is required. Please use this link to register:
https://www.directeventreg.com/registration/event/4832288

Following registration, an email confirmation will be sent including dial in details and unique conference call codes. Registration will remain open during the call however we recommend advance registration to access the event.

First quarter results will be available at:
https://investor.harvesthoc.com/financials/default.aspx

The live conference call webcast and replay will be available at:
https://investor.harvesthoc.com/financials/default.aspx

HARVEST HEALTH & RECREATION INC.
  Consolidated Balance Sheets
  (Amounts expressed in thousands of United States dollars, except share data)







March 31,

2021



December 31,

2020


ASSETS











Current assets:











Cash and cash equivalents




$

106,948



$

78,055


Restricted cash





3,000




4,542


Accounts receivable, net





9,477




5,051


Notes receivable, current portion





8,412




21,556


Related party notes receivable, current portion





10,313




10,052


Inventory, net





45,193




36,862


Other current assets





5,380




5,280


Total current assets





188,723




161,398


Notes receivable, net of current portion





11,036




18,211


Property, plant and equipment, net





161,663




176,827


Right-of-use assets for operating leases, net





98,921




60,843


Related party right-of-use assets for operating leases, net





5,564




5,621


Intangibles assets, net





272,886




272,118


Corporate investments





40,924




19,091


Acquisition deposits








50


Goodwill





116,176




116,041


Assets held for sale





6,581




6,585


Other assets





22,618




19,850


TOTAL ASSETS




$

925,092



$

856,635


LIABILITIES AND STOCKHOLDERS' EQUITY











LIABILITIES











Current liabilities:











Accounts payable




$

14,809



$

10,755


Other current liabilities





34,948




28,896


Contingent consideration, current portion





10,898




17,985


Income tax payable





26,826




17,504


Operating lease liability, current portion





2,061




2,906


Related party operating lease liability, current portion





142




135


Notes payable, current portion





29,713




20,910


Total current liabilities





119,397




99,091


Notes payable, net of current portion





240,046




244,066


Warrant liability





37,261




20,908


Operating lease liability, net of current portion





98,072




58,637


Related party operating lease liability, net of current portion





5,557




5,595


Deferred tax liability





53,082




53,082


Total liabilities associated with assets held for sale





718




718


Other long-term liabilities





53




63


TOTAL LIABILITIES





554,186




482,160


STOCKHOLDERS' EQUITY











Capital stock





686,899




667,248


Accumulated deficit





(316,729)




(293,607)


Stockholders' equity attributed to Harvest Health & Recreation Inc.





370,170




373,641


Non-controlling interest





736




834


TOTAL STOCKHOLDERS' EQUITY





370,906




374,475


TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY




$

925,092



$

856,635


HARVEST HEALTH & RECREATION INC.
  Consolidated Statements of Operations
  (Amounts expressed in thousands of United States dollars, except share and per share data)





For the three months ended
March 31,




2021



2020


Revenue, net of discounts


$

88,826



$

44,235


Cost of goods sold



(40,908)




(26,086)


Gross profit



47,918




18,149


Expenses









General and administrative



26,276




26,419


Sales and marketing



898




1,276


Share-based compensation



4,862




13,804


Depreciation and amortization



2,529




1,670


Total expenses



34,565




43,169


Operating income (loss)



13,353




(25,020)


Other (expense) income









Gain on sale of assets



1,795




2,419


Other income



1,504




9,050


Fair value of liability adjustment



(24,434)




6,945


Foreign currency gain (loss)



12




(138)


Interest expense



(8,717)




(4,550)


Loss before taxes and non-controlling interest



(16,487)




(11,294)


Income taxes



(6,481)




(3,794)


Net loss from continuing operations before non-controlling interest



(22,968)




(15,088)


Net loss from discontinued operations, net of tax






(384)


Net loss before non-controlling interest



(22,968)




(15,472)


Net (income) loss attributed to non-controlling interest



(154)




88


Net loss attributed to Harvest Health & Recreation Inc.


$

(23,122)



$

(15,384)


Net loss per share - basic and diluted


$

(0.06)



$

(0.05)


Attributable to Harvest Health and Recreation Inc.


$

(0.06)



$

(0.05)


Attributable to discontinued operations, net of tax


$



$


Weighted-average shares outstanding - basic and diluted



407,632,006




304,179,427


Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures as defined by the SEC. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measure calculated and presented in accordance with GAAP are included below. This information should be considered as supplemental in nature and not as a substitute for, or superior to, any measure of performance prepared in accordance with GAAP. Our management uses adjusted EBITDA to evaluate our operating performance and trends and make planning decisions. Our management believes adjusted EBITDA helps identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

Reconciliation of Non-GAAP Financial Measures
The table below reconciles Net income (loss) to Adjusted EBITDA for the periods indicated.



For the three months ended March 31,




2021



2020


Net loss (GAAP) before non-controlling interest


$

(22,968)



$

(15,472)


Add (deduct) impact of:









Net interest and other financing costs (1)



8,721




4,716


Income tax



6,481




3,794


Amortization and depreciation (2)



3,519




2,454


Gain on sale of assets



(1,795)




(2,419)


Fair value of liability adjustment



24,434




(6,945)


Other income



(1,504)




(9,050)


Foreign currency (gain) loss



(12)




138


Share-based compensation expense



4,862




13,804


Discontinued operations, net of tax






384


Other expansion expenses (pre-open)



3,172




3,341


Transaction & other special charges



2,006




447


Adjusted EBITDA (non-GAAP)


$

26,916



$

(4,808)



(1) Includes $4 and $166 of interest reported in cost of sales.

(2) Includes $990 and $784 of depreciation reported in cost of sales.

Forward-looking Statements
This press release contains "forward-looking statements," within the meaning of United States and Canadian securities laws. Such statements reflect current estimates, expectations and projections about future events and involve risks and uncertainties relating to future events and Harvest's performance, and actual events may differ materially from these forward looking statements, which may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. These forward looking statements include, without limitation, including statements regarding Trulieve Cannabis Corp.'s ("Trulieve") and Harvest's strategic business combination and the expected terms, timing and closing of the combination, estimates of pro-forma financial information of the combined company, Trulieve's and Harvest's expected financial performance for fiscal 2021, the combined operations and prospects of Trulieve and Harvest, the current and projected market and growth opportunities for the combined company and value for shareholders; our expectations for 2021 financial performance and targeted revenue; prospects for revenue growth and profitability in our core markets and in the U.S. cannabis industry generally; our continued growth in retail dispensary openings, same store sales growth, recreational sales in Arizona , and expanded cultivation and manufacturing operations; the development of federal and state cannabis regulatory framework in the United States applicable to multi-state operators, including a delay in, or a failure to, federally decriminalize cannabis in the United States , as well as such frameworks in Harvest's core markets; adverse changes in the application or enforcement of current laws, including those related to taxation; adverse changes in the public perception of cannabis; the effects of the weather, natural disasters, and health pandemics, including the novel coronavirus (COVID-19) on customer demand, Harvest's supply chain as well as its consolidated results of operation, financial position and cash flows; the ability of Harvest to develop Harvest's brand and meet its growth, revenue and profitability projections and objectives; its ability to generate sufficient cash flow to repay debt obligations and to fund operating expenses and future investment; the ability of Harvest to complete planned acquisitions that are accretive to its revenue; the ability of Harvest to obtain and/or maintain licenses to operate in the jurisdictions in which it operates or in which it expects or plans to operate; changes in general economic, business and political conditions, including changes in the financial markets, and, in particular, the ability of Harvest to raise debt and equity capital in the amounts and at the costs that it expects; the ability to locate and acquire suitable companies, properties or assets necessary to execute on Harvest's business plans; the ability of Harvest to execute planned store openings and secure cannabis supply at appropriate amounts and cost; fluctuations in the prevailing prices for cannabis and cannabis products in the markets that Harvest operates in and sources supply; its ability to resolve existing and future litigation and arbitrations on acceptable terms; and increasing costs of compliance with extensive government regulation. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods.

Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading "Risk Factors" in Harvest's Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission and in Harvest's Annual Information Circular, which was filed on SEDAR, both of which were filed on March 30, 2021 , and subsequent filings that Harvest makes with the Securities and Exchange Commission and SEDAR, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Harvest does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

About Harvest Health & Recreation Inc.
Headquartered in Tempe, Arizona , Harvest Health & Recreation Inc. is a vertically integrated cannabis company and multi-state operator. Since 2011, Harvest has been committed to expanding its retail and wholesale presence throughout the U.S., acquiring, manufacturing, and selling cannabis products for patients and consumers in addition to providing services to retail dispensaries. Through organic license wins, service agreements, and targeted acquisitions, Harvest has assembled an operational footprint spanning multiple states in the U.S. Harvest's mission is to improve lives through the goodness of cannabis. We hope you'll join us on our journey:   https://harvesthoc.com  

Facebook: @HarvestHOC
Instagram: @HarvestHOC
Twitter: @HarvestHOC

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/harvest-health--recreation-inc-reports-first-quarter-2021-financial-results-301287402.html

SOURCE Harvest Health & Recreation Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.

The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.

The country’s Ministry of Public Health issued an order this week stating that cannabis only be sold with a medical prescription, effectively ending a short-lived era of liberal recreational access.

Keep reading...Show less
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.

Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will reach AU$3.73 billion in 2024 and grow at an annual rate of 3.22 percent, culminating in market volume worth AU$4.53 billion by 2029.

However, Australia’s cannabis industry is still young. Despite there being a strong case for a regulated market, which was outlined in a July 2024 report by the Penington Institute, recreational use is not legal and medical access remains limited and regulated.

Keep reading...Show less
Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve.

Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among younger users, and cannabis companies are adapting their offerings to meet shifting demand.

Meanwhile, regulatory uncertainty, particularly surrounding the future of the US Farm Bill and state-level restrictions on hemp-derived cannabinoids, continues to challenge the market.

Despite these headwinds, production data and long-term growth forecasts suggest the cannabis industry remains on a promising — albeit turbulent — path. Read on for more on key trends to watch in 2025.

Consumption methods evolving post-legalization

Shifts in consumer behavior are reshaping markets across the board, and the cannabis industry is no exception.

While smoking remains the dominant method of cannabis consumption, a recent report from the Centers for Disease Control and Prevention highlights the growing popularity of edibles, vaping and dabbing.

The report notes that vaping and dabbing are particularly pronounced among younger adults.

A separate study published by the American Medical Association and funded in part by the Canadian Institutes of Health Research also points to how product preferences have changed among Canadian users since legalization in 2018.


The study indicates that while the use of flower, cannabis concentrates, oil, tinctures and topicals has decreased during that time, the use of vape cartridges, edibles and beverages has increased.

Edibles and beverages were legalized in Canada in late 2019, and Truss Beverage was one of the first players to introduce cannabis-infused drinks. Truss was a joint venture formed by Molson Coors Canada (TSX:TPX.A,TSX:TPX.B) and HEXO, a cannabis company that has since been acquired by Tilray Brands (TSX:TLRY,NASDAQ:TLRY).

In early 2020, Tilray launched a lineup of confectionery, wellness products and beverages through its subsidiary, High Park; Canopy Growth (TSX:WEED,NASDAQ:CGC) made a similar move. These companies gradually brought their products to the US as more states legalized cannabis for medical and/or recreational use.

Today, established cannabis brands typically offer edibles and beverages alongside their other products. Organigram Global (TSX:OGI,NASDAQ:OGI) is one of the newest US entrants, with its April acquisition of Collective Project providing immediate access to the US hemp-derived THC beverage market.

Growing awareness of health and wellness, potentially amplified by the pandemic-led adoption of health trackers, appears to be making an impact on the alcoholic beverage market.

A 2023 Gallup poll reveals a two decade decline in alcohol consumption, particularly among younger adults, suggesting a shift towards more health-conscious lifestyles within this demographic.

Craft beer production declined by 4 percent year-on-year in 2024, according to data collected by the Brewers Association. This marked the largest drop in the industry's history, excluding the pandemic. For small, independent craft breweries, 2024 marked the third consecutive year of declining production. A drop in the number of operating small breweries last year provides further evidence of this trend, with 501 closures in 2024 versus 434 openings.

Challenges in the alcohol market extend beyond the brewing industry, with the New York Times recently reporting the closure of a handful of nightclubs facing decreased alcohol sales alongside rising insurance and rent costs.

Meanwhile, cannabis lounges have been popping up across the US for the last several years. As of early 2025, several states had legalized or were in the process of implementing regulations for cannabis consumption lounges.

Hemp market growth despite regulatory uncertainty

The burgeoning hemp industry is another segment of the expanding cannabis market.

The legalization of industrial hemp — defined as cannabis with a THC concentration of 0.3 percent or less — through the 2018 Farm Bill led to initial investment and optimistic projections for CBD wellness products and various industrial applications. The sector’s rapid evolution also brought the rise of hemp-derived intoxicating cannabinoids, creating a market that presented both opportunities and complexities for participants.

However, after an initial boom, a lack of infrastructure and clearly defined regulations for CBD, as well as state-level variations and market oversupply, ultimately contributed to a quick retraction.

2024 was a pivotal year for the US hemp industry, as the hemp-related provisions of the 2018 Farm Bill — originally set to expire in September 2023, but extended to December 31, 2024 — created an urgent need to address critical issues like THC limits and the regulation of novel hemp-derived cannabinoids. A major point of contention was the proposed shift from defining hemp based on Delta-9 THC concentration (0.3 percent or less) to “total THC,” which includes THCA.

This change had the potential to significantly impact farmers and processors, as many hemp varieties that are compliant under the Delta-9 THC rule could exceed the 0.3 percent limit when THCA is included.

Various bills and amendments were proposed in 2024 as part of the Farm Bill discussions, each with different approaches to regulating hemp. Separate regulatory frameworks for industrial hemp and hemp grown for cannabinoids were suggested, and many states took their own action, leading to a patchwork of regulations and even outright bans.

Despite challenges, data from the US Department of Agriculture suggests signs of recovery.

The department's annual National Hemp Report from 2024 points to an 18 percent increase in industrial hemp production value between 2022 and 2023, with output growth seen in specific sectors like floral (18 percent), fiber (133 percent) and seed hemp (414 percent). The 2025 report from the Department of Agriculture indicates further expansion, with notable increases observed in both acreage (up 64 percent from 2023) and value (46 percent).

The 2024 Farm Bill ultimately did not pass, and right now the hemp industry is operating under a temporary extension of the 2018 Farm Bill under the American Relief Act of 2025, signed into law on December 21, 2024.

The 2018 Farm Bill is now set to expire on September 30, 2025.

While analysts for Markets and Markets project that the North American hemp industry will grow at a CAGR of 22.4 percent and ultimately reach a valuation of US$30.24 billion by 2029, the future of the industry will be heavily influenced by the outcome of the ongoing Farm Bill discussions.

US cannabis legalization remains stalled

Although there is clear demand for cannabis products, the now-defunct rescheduling process in the US is likely to continue casting a shadow of uncertainty over the industry's long-term trajectory.

Legal and procedural delays, including allegations of improper conduct and bias within the US Drug Enforcement Administration (DEA), led to hearing cancellations, and the new administration of US President Donald Trump has brought leadership changes to key agencies like the DEA and the Department of Justice.

Terry Cole, who Trump nominated to be DEA administrator on February 11, has a history of opposing cannabis legalization in the country. Similarly, Pam Bondi, Trump’s pick to lead the justice department, staunchly opposed a movement to legalize medical cannabis during her tenure as Florida’s attorney general.

While there have been bipartisan efforts in Congress to end federal cannabis prohibition and establish regulations for eventual legalization, the DEA’s actions and statements indicate a potential stall or reversal of progress.

In addition to that, new research is adding complexity to the debate.

A study published in the American Journal of Psychiatry this past March highlights an association between the use of high-potency cannabis strains and increased risks of psychosis, a factor that may not have been fully considered by the Department of Health and Human Services. As stronger cannabis strains become more widely available, a reassessment of their potential health risks may be required.

Investor takeaway

While the cannabis industry holds promise for growth and innovation, investors must remain acutely aware of the regulatory uncertainties and market volatility that will undoubtedly shape its trajectory in the years to come.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Person touching a cannabis plant; Australia map in flag colours.

ASX Cannabis Stocks: 10 Biggest Companies

While Australia has yet to legalise all forms of cannabis, the country is a growing medical cannabis and hemp market, with many companies manufacturing, researching and exporting the plant-based product.

Medical cannabis was federally legalised in 2016, and the export of cannabis from Australia was legalised in 2018. As for recreational use, the only state to legalise recreational use and possession so far is the Australian Capital Territory, which did so in 2020, but it did not establish a regulated recreational cannabis market.

The country's medical cannabis market has been steadily expanding in size and scope. A Penington Institute report shows that Australians spent approximately AU$400 million on medicinal cannabis in the first half of 2024, 72 percent higher than the AU$234 million they spent over the entirety of 2022.

Keep reading...Show less
Cannabis leaves, gavel.

Cannabis Round-Up: Rescheduling Faces New Roadblocks, SAFER Banking Act Gets Another Look

February 2025 was characterized by an evolving legislative landscape and important financial updates from major players.

These developments underscore the complex and dynamic nature of the sector as it continues to navigate legal, financial, and regulatory challenges while experiencing ongoing growth and evolution.

Discussions around cannabis rescheduling, changes in federal agency leadership, state-level legalization efforts, and financial reports from key companies all contributed to a month of notable activity in the cannabis space.

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: Banking Reform and Rescheduling De-Prioritized as Trump Takes Office

As a new year began, the cannabis industry saw a range of impactful events in January.

Legal obstacles continued to impede progress on a once-promising attempt to reschedule cannabis in the US, and President Donald Trump's leadership choices for key agencies are diminishing hopes it can be accomplished.

Meanwhile, cannabis banking reform won't be discussed at Wednesday's (February 5) meeting of the Standing Senate Committee on Banking, Commerce and the Economy, and Congress seems in no rush to address it.

Keep reading...Show less

Latest Press Releases

Related News

×